Method for enhancing gut absorption

• US 5,288,703 A
• Filed: 10/07/1992
• Issued: 02/22/1994
• Est. Priority Date: 10/07/1991
• Status: Expired due to Term

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Wilmore, Douglas
• Primary Examiner(s): Waddell, Frederick E.
• Assistant Examiner(s): Henley, III, Raymond J.
• Application Number:
  US07/957,174
• Time in Patent Office: 503 Days
• Field of Search: 514/2, 514/563
• US Class Current: 514/3.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

The present invention provides a method for enhancing the gut absorption in a mammal. Specifically, gut absorption in a mammal can be enhanced by the administration of glutamine, or glutamine equivalent, in combination with one or more agents, said agents selected from the group consisting of growth hormone (GH), an agent capable of enhancing endogenous GH production, insulin like growth factor 1 (IGF-1), or an agent capable of enhancing endogenous IGF-1 production.

Claims

1. A method of increasing gut absorption of nutrients in a mammal, comprising co-administering to said mammal a therapeutically effective amount of glutamine and a therapeutically effective amount of growth hormone.

3. The method of claims 1 or 2, wherein said mammal is a human.

4. The method of claims 1 or 2, wherein said composition is administered parenterally.

5. The method of claims 1 or 2, wherein said composition is administered enterally.

6. The method of claims 1 or 2, wherein said therapeutically effective amount of an agent contains a dosage of said growth hormone in the range of 0.05 to 0.3 mg/kg/day.

7. The method of claims 1 or 2, wherein said therapeutically effective amount of glutamine contains a dosage of said glutamine in the range of 0.2 to 3 gm/kg/day.

8. The method of claims 1 or 2, wherein said treatment is a result of malabsorption syndrome.

9. The method of claim 8, wherein said malabsorption syndrome is a result of short gut syndrome.

10. The method of claim 9, wherein said malabsorption syndrome is a result of surgical excision of all or a portion of the small intestine.

11. The method of claim 10, wherein said surgical excision is a result of a condition selected from the group consisting of;

traumatic disease, congenital atresia, abdominal radiation injury, chronic adhesive obstruction, and mesenteric tumors.

12. The method of claim 8, wherein said malabsorption syndrome is a result a pathological condition selected from the group consisting of;

meconium ileus, volvulus, gastroschisis, necrotizing enterocolitis, Hirschprung'"'"'s disease, inflammatory bowel disease, vascular damage, mesenteric tumors, infectious diarrhea, secretory diarrhea and AIDs-related diarrhea.

13. The method of claim 12, wherein said vascular damage is selected from the group consisting of;

thrombosis of the superior mesenteric artery, thrombosis of the superior mesenteric vein, thrombosis of the portal vein.

2. A method of increasing gut absorption of nutrients in a mammal, comprising co-administering to said mammal a therapeutically effective amount of glutamine and a therapeutically effective amount of growth hormone, wherein said mammal has undergone bowel resection greater than eleven months prior to said co-administration.